Çermik, TFYüksel, MKarlikaya, CDoganay, LTüre, MBerkarda, S2024-06-122024-06-1220030914-7187https://doi.org/10.1007/BF03006603https://hdl.handle.net/20.500.14551/22776Purpose: The aim of this study was to evaluate the relationship between Tl-201 tumor uptake, chemotherapeutic response, metastasis, p53 status and survival in non-small cell lung cancer (NSCLC). Methods: A total of 23 patients underwent Tl-201 SPECT. In 9 patients, 2nd Tl-201 SPECT study were performed 1 week after the 3rd cycle of chemotherapy (ChT), and early (ER) and delayed (DR) tumor/normal lung ratios and retention indices (RI) were obtained. In 15 patients p53 status was assayed with immuno-histochemical staining. The patients were divided into subgroups after the 3rd cycle of ChT; responders [R(+) (n = 10)] and non-responders [R(-) (n = 13)], distant metastasis [(M-1) n =11] and [(M-0) n = 12], and mutant p53 status [p(+) n = 7, p53(-) n = 8]. Results: The differences for ER, DR and RI values between all of the subgroups were not statistically significant. ER and DR of responders decreased significantly after ChT; from to 2.46 to 1.36 (p = 0.04) and 2.29 to 1.53 (p = 0.04), respectively. In the non-responder group, both ER and DR slightly increased after ChT (p > 0.05). Conclusion: Our results suggest that in NSCLC, there was a weak correlation between higher Tl-201 ratios and positive response to chemotherapy, absence of distant metastasis, and p53(-) status. Significant Tl-201 uptake decrease after chemotherapy indicates that delayed Tl-201 uptake can be used in evaluating the chemotherapeutic response.en10.1007/BF03006603info:eu-repo/semantics/closedAccessNon-Small Cell Lung CancerTl-201 SPECTChemotherapySurvivalMetastasisP53Emission Computed-TomographyTc-99m MibiCarcinomaIndicatorPetAbnormalitiesExpressionResistancePrognosisLesionsArticle175369374Q4WOS:0001849602000052-s2.0-1814444369512971634Q2